Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

医学 内科学 危险系数 肿瘤科 乳腺癌 中期分析 临床终点 人口 比例危险模型 置信区间 癌症 随机对照试验 妇科 环境卫生
作者
Nadia Harbeck,Priya Rastogi,Miguel Martín,Sara M. Tolaney,Zhimin Shao,Peter A. Fasching,Chiun‐Sheng Huang,Georgina Garnica Jaliffe,A. Tryakin,Matthew P. Goetz,Hope S. Rugo,Elżbieta Senkus,Laura Testa,Mariette Andersson,Kenji Tamura,Lucia Del Mastro,Guenther G. Steger,Hans Kreipe,Roberto Hegg,Joohyuk Sohn,Valentina Guarneri,Javier Cortés,E. Hamilton,Valérie André,Ran Wei,Susana Barriga,S. Sherwood,Tammy Forrester,Montserrat Muñoz,Ashwin Shahir,Belén San Antonio,Sarah C. Nabinger,Masakazu Toi,Stephen Johnston,Joyce O’Shaughnessy,M.M. Jimenez,Stephen Johnston,F. Boyle,Guenther G. Steger,Patrick Neven,Zefei Jiang,Mario Campone,Jens Huober,Chikako Shimizu,İrfan Çiçin,Andrew Wardley,Sara M. Tolaney,G. Gomez Abuin,J. J. Zarba,Elgene Lim,Peter van ’t Sant,Naishun Liao,Bo Christiansen,Natalja Eigėlienė,J. Martin-Babau,Johannes Ettl,D. Mavroudis,Joanne Chiu,Katalin Boér,R. Nagarkar,Shani Paluch–Shimon,Luca Moscetti,Yoshiatsu Sagara,S.-B. Kim,Rui M. B. Maciel,Vivianne C. G. Tjan‐Heijnen,Reuben Broom,Aleksandra Łacko,M. Schenker,Nikita Volkov,Yoon Sim Yap,Maria A. Coccia-Portugal,J. Ángel García Sáenz,Anne Andersson,Tai-Jong Chao,Erhan Gökmen,Hakan Harputluoğlu,O. Berzoy,Debra A. Patt,Heather L. McArthur,Helen K. Chew,Pavani Chalasani,Peter A. Kaufman,Karen L. Tedesco,Stephanie L. Graff
出处
期刊:Annals of Oncology [Elsevier]
卷期号:32 (12): 1571-1581 被引量:277
标识
DOI:10.1016/j.annonc.2021.09.015
摘要

Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis.This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for ≥5 years ± abemaciclib for 2 years. Cohort 1 enrolled patients with ≥4 positive axillary lymph nodes (ALNs), or 1-3 positive ALNs and either grade 3 disease or tumor ≥5 cm. Cohort 2 enrolled patients with 1-3 positive ALNs and centrally determined high Ki-67 index (≥20%). The primary endpoint was IDFS in the intent-to-treat population (cohorts 1 and 2). Secondary endpoints were IDFS in patients with high Ki-67, DRFS, overall survival, and safety.At the primary outcome analysis, with 19 months median follow-up time, abemaciclib + ET resulted in a 29% reduction in the risk of developing an IDFS event [hazard ratio (HR) = 0.71, 95% confidence interval (CI) 0.58-0.87; nominal P = 0.0009]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (HR = 0.70, 95% CI 0.59-0.82; nominal P < 0.0001) and DRFS (HR = 0.69, 95% CI 0.57-0.83; nominal P < 0.0001) benefit was maintained. The absolute improvements in 3-year IDFS and DRFS rates were 5.4% and 4.2%, respectively. Whereas Ki-67 index was prognostic, abemaciclib benefit was consistent regardless of Ki-67 index. Safety data were consistent with the known abemaciclib risk profile.Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67 index. Overall, the robust treatment benefit of abemaciclib extended beyond the 2-year treatment period.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
闪闪青雪完成签到,获得积分10
1秒前
Liar完成签到,获得积分10
1秒前
群阿完成签到,获得积分10
1秒前
双马尾小男生完成签到,获得积分10
2秒前
2秒前
Chu_JH完成签到,获得积分10
3秒前
聖璕完成签到,获得积分10
3秒前
万能图书馆应助wujiwuhui采纳,获得10
3秒前
子车茗应助Ni采纳,获得10
4秒前
4秒前
薯片完成签到,获得积分20
5秒前
6秒前
COC完成签到,获得积分10
6秒前
芝麻福福完成签到,获得积分10
6秒前
bkagyin应助yyyyyy采纳,获得10
6秒前
健壮小懒猪完成签到,获得积分10
7秒前
朱哈哈完成签到,获得积分20
8秒前
双马尾小男生2完成签到,获得积分10
8秒前
sudeior关注了科研通微信公众号
9秒前
lagrange完成签到,获得积分20
9秒前
科研文献搬运工举报小薛求助涉嫌违规
9秒前
陈__发布了新的文献求助10
10秒前
单纯行天完成签到,获得积分20
11秒前
vocrious完成签到 ,获得积分10
11秒前
嵇南露完成签到,获得积分10
12秒前
杨佳于发布了新的文献求助10
12秒前
S欣完成签到,获得积分10
12秒前
12秒前
两先生完成签到 ,获得积分10
12秒前
白潇潇完成签到,获得积分10
13秒前
yym完成签到,获得积分10
13秒前
13秒前
Fanzhijuan完成签到,获得积分10
14秒前
小天狼星完成签到,获得积分10
14秒前
hs完成签到,获得积分10
15秒前
Atlantis完成签到,获得积分10
16秒前
lezbj99发布了新的文献求助10
16秒前
Zhaowx完成签到,获得积分10
16秒前
Drwenlu完成签到,获得积分10
16秒前
brick2024完成签到,获得积分10
17秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
叶剑英与华南分局档案史料 500
Foreign Policy of the French Second Empire: A Bibliography 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3147001
求助须知:如何正确求助?哪些是违规求助? 2798279
关于积分的说明 7827502
捐赠科研通 2454919
什么是DOI,文献DOI怎么找? 1306492
科研通“疑难数据库(出版商)”最低求助积分说明 627808
版权声明 601565